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Summary The aim of this double-blind, double-dummy, crossover, randomised, pilot
study was to explore the acute effects of adding salmeterol and tiotropium in
patients with stable COPD. A total of 20 outpatients with stable COPD were enrolled.
Single doses of 18-mg tiotropium, 50-mg salmeterol, and 18-mg tiotropiumþ 50-mg
salmeterol were given. Serial measurements of forced expiratory volume in 1 s (FEV1)
were performed over 24 h. The mean maximum increases in FEV1 from pre-dosing
value on each of the dosing days were 0.165 l (95% CI: 0.098–0.232) for tiotropium,
0.241 l (95% CI: 0.151–0.332) for salmeterol, and 0.290 l (95% CI: 0.228–0.353) for the
combination and occurred 4 h after inhalation of tiotropium or salmeterol and 3 h
after the combination. At 12h, the mean increases in FEV1 from pre-dosing value
were 0.071 l (95% CI: 0.001–0.141; P ¼ 0:047) for tiotropium, 0.069 l (95% CI: 0.018-
0.120; P ¼ 0:010) for salmeterol, and 0.108 l (95% CI: 0.047–0.170; P ¼ 0:001) for the
tiotropiumþ salmeterol combination. Only the difference between salmeterol and
tiotropiumþ salmeterol was statistically significant (P ¼ 0:009). At 24 h, the mean
FEV1 value was still higher than the mean pre-dosing value for tiotropium (0.042 l;
95% CI: 0.012–0.097; P ¼ 0:119) and the tiotropiumþ salmeterol combination
(0.051 l; 95% CI: 0.015–0.087; P ¼ 0:007), but not for salmeterol alone (0.013 l; 95%
CI: 0.041–0.014; P ¼ 0:324). The FEV1 area under the curve (AUCs012h) were
1.657 l (95% CI: 1.152–2.162) for tiotropium, 2.068 l (95% CI: 1.385–2.752) for
salmeterol, and 2.541 l (95% CI: 1.954–3.129) for tiotropiumþ salmeterol. Only the
difference between tiotropium and the tiotropiumþ salmeterol combination
was statistically significant (P ¼ 0:01). The FEV1 AUCs024h were 2.854 l (95% CI:
1.928–3.780) for tiotropium, 2.786 l (95% CI: 1.913–3.660) for salmeterol, and 3.640 l
(95% CI: 2.674–4.605) for tiotropiumþ salmeterol. All differences between treat-
ments were not statistically significant (P40:05). These results seem to indicate that
the use of the tiotropiumþ salmeterol combination is more efficacious than the single
agents alone, but the once-daily administration of the two drugs is inadvisable due to
the broncholytic profile of salmeterol.
& 2004 Published by Elsevier Ltd.
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Introduction
Tashkin and Cooper1 have recently suggested to add
salmeterol or formoterol, which are long-acting b2-
agonists, to tiotropium bromide, which is a long-
acting antimuscarinic agent, in patients suffering
from COPD with more severe symptoms (stage III or
IV of the GOLD classification2). At present, only one
combination study with tiotropium bromide and
formoterol has been published.3 Its results indicate
that formoterol and tiotropium have different
profiles (formoterol has faster onset of action and
greater bronchodilating effect, tiotropium has
longer duration of action, which allows once a
day administration) that make both agents attrac-
tive alternatives in the treatment of stable COPD.
Moreover, the two drugs appear complementary:
tiotropium ensures prolonged bronchodilation,
whereas formoterol adds fast onset and a greater
peak effect.
However, because formoterol is given twice daily,
but tiotropium is required only once daily, the
challenge is to develop a combined inhaler that can
be employed on a daily basis.4 The pharmacody-
namic characteristics of salmeterol might permit
the once-daily contemporaneous administration of
the two drugs that could simplify the therapy.5
Unfortunately, studies of the combination of
tiotropium and salmeterol have not been pub-
lished.
For this reason, the aim of this study was to
explore the acute effects of adding salmeterol to
tiotropium in patients with stable COPD.
Materials and methods
Subjects
The study group consisted of 20 outpatients (17
males, 3 females; mean age 72.6 years, 95% CI:
69.1–76.0) clinically diagnosed with stable COPD.
Mean baseline forced expiratory volume in 1 s
(FEV1) was 1.10 l (95% CI: 0.91–1.29) and mean
forced vital capacity (FVC) was 1.85 l (95% CI:
1.62–2.07). All patients fulfilled the criteria pro-
posed by GOLD guidelines:1 they had cough, sputum
production, or dyspnea, and/or a history of
exposure to risk factors for the disease. The
diagnosis was confirmed by spirometry. The pre-
sence of a postbronchodilator FEV1o80% of the
predicted value in combination with an
FEV1=FVCo70% confirms the presence of airflow
limitation that was not fully reversible. Reversi-
bility 30min after salbutamol 200-mg ranged from
1% to 26%. Patients with allergic rhinitis, atopy,
positive skin test, or with a total blood eosinophil
count over 400mm3 were excluded. Patients were
also excluded if they had any co-existing cardio-
vascular or lung disorder. Table 1 illustrates the
anthropometric data and pulmonary function of
patients.
The study was carried out according to the rules
of the declaration of Helsinki. The institutional
Ethics Committee approved it. All patients pro-
vided written informed consent to participate in
the study.
Protocol
The study was performed using a double-blind,
double-dummy, crossover, randomised design. Pa-
tients received single doses of 18-mg tiotropium
bromide dry powder capsules delivered via a
breath-actuated powder inhaler (Handihaler),
50-mg salmeterol micronised powder formulation
administered via a breath-activated multidose
powder inhaler (Diskus), and their combination, in
randomised sequence on 3 non-consecutive days.
The washout period between the test days was at
least 168 h (7 days) to avoid any carryover effect of
tiotropium6 or salmeterol. Each treatment was
administered at the same time of the day (between
7 AM and 9 AM). No other oral bronchodilator was
permitted for 1 week before and during the study,
whereas inhaled short-acting and long-acting
bronchodilators were nor permitted for at least
12- and 24 h prior to each test, respectively.
Consumption of cola drinks, coffee, tea, and
smoking in the hours before and during the
investigation were also avoided.
Physiological measurements
On test days, measurements of FEV1; FVC; slow vital
capacity (SVC) and inspiratory capacity (IC) were
recorded just before dosing, and 30-, 60-, 90-, 120-,
180-, 240-, 360-, 480-, 600-, 720-, and 1440min
after the study drug administration. Measurements
were performed according to American Thoracic
Society criteria.7 IC was determined by a slow
manoeuvre (slow inspiration until maximum volume
after regular tidal breathing). Spirometry was
conducted in triplicate, while the patient was in a
seated position. The largest FEV1 and FVC were
recorded after examining all of the acceptable
curves, even if they were not from the same curve.
SVC was taken as a slow expiration from total
lung capacity. The largest SVC was recorded in
a manoeuvre prior to the forced expiratory
ARTICLE IN PRESS
The functional impact of adding salmeterol and tiotropium in patients with stable COPD 1215
flow-volume loops. At the same time points, pulse
rate and oxygen saturation by pulse oximetry (SpO2)
were also measured.
Statistical analysis
This was a pilot study and the first known
comparison of salmeterol and tiotropium with their
combination. In view of the lack of previous
experiences, no statistical hypotheses were drawn
and consequently no formal sample size calculation
was made. The use of a pilot study such as the
current study in clinical research is a well-estab-
lished scientific procedure and only through the use
of a pilot study can statisticians clarify data
distributions and determine appropriate sample
sizes for full-scale clinical trials.
Comparisons of baseline characteristics among
the three treatments were performed by ANOVA
analysis and Fisher’s exact test. Analysis of spiro-
metric data, pulse rate and SpO2 were performed
using the Student’s t-test for paired variables. The
time-averaged changes in the 24-h period following
each drug administration were compared by means
of the distribution-free crossover analysis.8 As an
expression of the total effect of each treatment,
the areas under the FEV1 time–response curves
(AUC) were calculated for each patient by means of
the trapezoidal rule. Comparisons of AUC values
among the three treatments were performed by
ANOVA analysis and Fisher’s exact test. A prob-
ability level of Po0.05 was considered significant
for all tests.
Results
All 20 patients completed the 3-day study. There
were no significant differences between the base-
line FEV1 values of the three treatment groups
(P ¼ 0:442).
Rate of onset of action
The onset of action was evaluated as mean change
from baseline of FEV1 at 30min and mean time to
improve FEV1 by 12% after the inhalation of each
single treatment.
The change in FEV1 30min after inhalation of
salmeterol alone (0.058 l; 95% CI: 0.032–0.083) was
greater than that induced by tiotropium alone
(0.037 l; 95% CI: 0.013–0.062), but not than that
elicited by tiotropiumþ salmeterol (0.121 l; 95% CI:
0.073–0.170) (Fig. 1). The difference between
the improvement after salmeterol and that
after tiotropium was not statistically significant
(P ¼ 0:231), but the differences between the
improvement after tiotropiumþ salmeterol and
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Table 1 Anthropometric data and pulmonary function of patients.
Patient Sex Age (yr) Smoking habit
(p/y)
FEV1 (%
predicted)
FVC (%
predicted)
Reversibility
(% baseline)
1 M 81 Ex 40 60 62 2
2 M 78 Ex 30 37 53 2
3 M 76 60 34 48 5
4 F 83 Ex 20 55 58 14
5 M 71 180 70 75 20
6 F 58 30 74 82 7
7 M 59 80 44 56 5
8 M 72 60 23 61 8
9 M 80 40 54 62 9
10 M 70 90 34 39 19
11 M 61 70 16 32 22
12 M 79 40 24 45 9
13 F 73 50 76 94 1
14 M 78 40 50 59 26
15 M 69 80 53 61 4
16 M 75 180 43 72 17
17 M 77 20 26 42 20
18 M 68 50 28 48 5
19 M 65 55 44 54 6
20 M 78 110 25 29 9
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that after tiotropium alone and salmeterol alone
were statistically significant (P ¼ 0:014 and 0:026;
respectively).
Eight patients out of 20 were unable to achieve a
12% improvement in FEV1 after tiotropium and 2 did
not show this change after salmeterol, whereas all
patients improved of at least 12% after salmeter-
olþ tiotropium. Salmeterol was associated with a
rise in FEV1 of at least 12% after 125min (95% CI:
67–183), tiotropium after 107min (95% CI: 75–139)
and the combination therapy after 79min (95% CI:
43–115). Eleven patients presented this type of
improvement after all the three treatments.
However, in these patients, the mean improvement
was reached 112min (95% CI: 78–146) after
tiotropium, 123min (95% CI: 29–217) after salme-
terol, and 57min 95% CI: 36–78) after salmeterolþ
tiotropium.
When the onset of action was evaluated as mean
change from baseline of IC at 30min after the
inhalation of each single treatment (Fig. 1), we
observed that tiotropium alone was unable to
modify this parameter (0.003 l; 95% CI: 0.052–
0.059; P ¼ 0:896), whereas both salmeterol alone
(0.077 l; 95% CI: 0.029–0.125; P ¼ 0:003) and
tiotropiumþ salmeterol (0.210 l; 95% CI: 0.050–
0.370; P ¼ 0:013) improved IC in a statistically
significant manner.
Maximum response
The mean maximum increases in FEV1 from pre-
dosing value on each of the dosing days were 0.165 l
(95% CI: 0.098–0.232) for tiotropium, 0.241 l (95%
CI: 0.151–0.332) for salmeterol, and 0.290 l (95% CI:
0.228–0.353) for the combination (Fig. 2) and
occurred 4 h after inhalation of tiotropium or
salmeterol and 3 h after that of the combination.
Time course of bronchodilating effect
All treatments significantly sustained their bronch-
odilating effect over pre-dosing value on each of
the dosing days. The actual data of FEV1 before and
after the three treatments are shown in Fig. 2.
At 12 h, the mean increases in FEV1 from pre-
dosing value were 0.071 l (95% CI: 0.001–0.141;
P ¼ 0:047) for tiotropium, 0.069 l (95% CI: 0.018–
0.120; P ¼ 0:010) for salmeterol, and 0.108 l
(95% CI: 0.047–0.170; P ¼ 0:002) for the tiotro-
piumþ salmeterol combination. Only the differ-
ence between tiotropium and tiotropiumþ
salmeterol was statistically significant (P ¼ 0:009).
At 24 h, the mean FEV1 value was still higher than
the mean pre-dosing value for tiotropium (0.042 l;
95% CI: –0.012–0.097; P ¼ 0:119) and the tiotro-
piumþ salmeterol combination (0.051 l; 95% CI:
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Figure 1 Mean changes (7SE) in FEV1 (L) and IC (L) from
pre-dosing value on each of the dosing days up to 90min
after inhalation of tiotropium 18-mg (squares), salmeterol
50-mg (rhombi), and tiotropium 18-mgþ salmeterol 50-mg
(triangles). Po0:01; and Po0:001 vs. baseline.
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Figure 2 Mean changes (7SE) in FEV1 (l) from pre-dosing
value on each of the dosing days up to 24 h after
inhalation of tiotropium 18-mg (squares), salmeterol
50-mg (rhombi), and tiotropium 18-mgþ salmeterol
50-mg (triangles). Po0:05; Po0:01; and Po0:001
vs. baseline.
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0.015–0.087; P ¼ 0:008), but not for salmeterol
alone (–0.013 l; 95% CI: –0.041–0.014; P ¼ 0:324).
At this time point, the differences between
tiotropium and salmeterol and salmeterol and
tiotropiumþ salmeterol, but not that between
tiotropium and tiotropiumþ salmeterol, were sta-
tistically significant (P ¼ 0:010; 0:006; and 0:752;
respectively).
The improvements of FVC over baseline values
were not statistically significant both at 12 and 24 h
after all the three treatments (Fig. 3), whereas the
change from baseline in IC at 12 h after tiotro-
piumþ salmeterol was statistically significant
(P ¼ 0:017) (Fig. 3).
FEV1 area under the curves
Tiotropium, salmeterol, and their combination
significantly improved the AUC for FEV1 measured
over a period of 12 or 24 h (Fig. 4). The FEV1
AUCs012 h were 1.657 l (95% CI: 1.152–2.162) for
tiotropium, 2.068 l (95% CI: 1.385–2.752) for sal-
meterol, and 2.541 l (95% CI: 1.954–3.129) for
tiotropiumþ salmeterol. Only the difference be-
tween tiotropium and the tiotropiumþ salmeterol
combination was statistically significant (P ¼ 0:01).
The FEV1 AUCs024 h were 2.854 l (95% CI: 1.928–
3.780) for tiotropium, 2.786 l (95% CI: 1.913–3.660)
for salmeterol, and 3.640 l (95% CI: 2.674–4.605)
for tiotropiumþ salmeterol. All differences be-
tween treatments were not statistically significant
(P40:05).
Pulse rate and oxygen saturation
No statistically significant (P40:05) modifications
from baseline in pulse rate and SpO2 were
detected. Also ,the differences between the three
treatments were always not significant (P40:05)
(Fig. 5).
Discussion
The parasympathetic nervous system is the domi-
nant neuronal pathway in the control of airway
smooth muscle tone.9 Sympathetic nerves may
control tracheobronchial blood vessels, but no
innervation of human airway smooth muscle
has been demonstrated. b-Adrenoceptors, how-
ever, are abundantly expressed on human airway
smooth muscle and activation of these receptors
causes its relaxation.9 Interestingly, it has been
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Figure 3 Mean changes (7SE) in FVC (l) and IC (l) from
pre-dosing value on each of the dosing days up to 24 h
after inhalation of tiotropium 18-mg (squares), salmeterol
50-mg (rhombi), and tiotropium 18-mgþ salmeterol
50-mg (triangles). Po0:05; Po0:01; and Po0:001
vs. baseline.
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Figure 4 Mean change (7SE) from pre-dosing value on
each of the dosing days in FEV1 AUCs. AUC0–12 h¼ area
under the FEV1 vs. time curve baseline in FEV1 AUC012 h
during the first 12-h serial pulmonary function testing;
AUC024 h¼ area under the FEV1 vs. time curve during
24-h serial pulmonary function testing. Blank, tiotropium
18-mg; black, salmeterol 50-mg; dotted, tiotropium 18-
mgþ salmeterol 50-mg. Po0:01 vs. tiotropium.
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documented that b-adrenoceptors also mediate
inhibition of acetylcholine release from the neu-
roeffector junctions of the pulmonary, parasympa-
thetic nerves most probably by the liberation
of inhibitory prostaglandins from the airway
mucosa,10 although recently it has been sug-
gested that b2-adrenoceptor agonists attenuate
cholinergic neurotransmission in isolated bovine
trachealis model by a mechanism involving KCa
channels.11
Bronchodilation may be obtained either by
stimulating the adrenergic receptors with b2-
agonists, or by inhibiting the action of acetylcho-
line at muscarinic receptors with anticholinergic
agents.9 Since b-agonists and anticholinergic agents
are distinct classes of drugs with different mechan-
isms of action that may involve different sites
within the airways and b-agonists have the poten-
tial for directly influencing the cholinergic system,
an additive effect may be expected.9 In effect, a
number of clinical studies have shown a benefit of
combining a short-acting b-agonist with short-
acting anticholinergic agents such as ipratropium
and oxitropium in COPD.12–15 For this reason,
treatment guidelines recommend concomitant use
of anticholinergic agents and inhaled b2-agonists as
severity of COPD progresses.2,16,17 Interestingly,
when combined treatment with a b2-agonist and an
antimuscarinic agent is required, there is evidence
that long-acting b2-agonists may represent the
most effective option for combined treatment with
ipratropium.18
Considering that all long-acting bronchodilators
have demonstrated superior efficacy on at least
some outcomes compared with short-acting
bronchodilators, Tashkin and Cooper1 have sug-
gested that the use of short-acting bronchodilators
should be restricted to symptomatic relief for
patients with infrequent, intermittent symptoms,
and long-acting bronchodilators should be used for
maintenance treatment. Since both salmeterol and
formoterol in combination with ipratropium have
additive effects on lung function and other out-
comes, it seems reasonable to expect that the
combination of long-acting anticholinergics and
long-acting b2-agonists will provide additive bene-
fits similar to those observed with a combination of
short-acting bronchodilators.1
Actually, a recent study showed that formoterol,
either alone or in combination with tiotropium,
elicited a significantly faster onset of action and
showed a trend for a greater maximum bronchodi-
lation than tiotropium alone.3 At 24 h, mean FEV1
continued to be significantly higher than pre-dosing
value following tiotropium and tiotropiumþ
formoterol. However, at this time point, the
differences between treatments were not
significant.
Also, in this study the addition of salmeterol to
tiotropium elicited a significantly faster onset of
action and showed a trend for a greater maximum
bronchodilation than single drugs alone. Moreover,
we observed that at 24 h, the mean FEV1 value was
still higher than the mean pre-dosing value for
tiotropium and the tiotropiumþ salmeterol combi-
nation, but the differences between tiotropium
and salmeterol, and salmeterol and tiotropiumþ
salmeterol were statistically significant. These
findings support the possibility of combining tio-
tropium and salmeterol in patients suffering from
stable COPD, but exclude the once-daily co-admin-
istration of the two drugs.
The potential of salmeterol and tiotropium to
fast their onset of action when combined is worthy
of attention considering that both agents elicit a
slow onset of action.19,20 Ethier et al.21 documen-
ted that at the lowest concentration of salmeterol
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Figure 5 Mean changes (7SE) in heart rate (beats/min)
and pulse oximetry (SpO2) (%) from pre-dosing value on
each of the dosing days up to 24 h after inhalation of
tiotropium 18-mg (squares), salmeterol 50-mg (rhombi),
and tiotropium 18-mgþ salmeterol 50-mg (triangles).
Po0:05; Po0:01; and Po0:001 vs. baseline.
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needed to maximally stimulate cAMP accumulation,
this long-acting b2-agonist antagonised muscarinic
inhibition of cAMP accumulation and altered ago-
nist binding to muscarinic receptors in bovine
trachealis cells. Because salmeterol altered ago-
nist, but not antagonist, binding and appeared to
have an effect on the proportion of high-affinity
binding sites, Ethier et al.21 speculated that
salmeterol has a low-affinity binding interaction
with the muscarinic receptor/G-protein complex
itself or reversibly alters the plasma membrane
environment surrounding the complex. In any
case, these effects of salmeterol did not
depend on stimulation of b2-adrenoceptors. If this
finding were also true for human airways, we
could speculate that salmeterol reduces the
bronchospastic activity of endogenous acetylcho-
line, without influencing the effect of tiotropium.
Salmeterol has also high affinity for muscarinic
receptors22 and this indicates a potential
for amplifying the action of tiotropium. However,
the question of whether high local concentrations
after inhalation of salmeterol could contribute
to their therapeutical effects by antagonism
with ACh on muscarinic receptors remains to be
answered.22
Although our results indicate that a combination
of tiotropium and salmeterol is more effective than
single drugs alone in inducing bronchodilation in
patients suffering from COPD, there is a funda-
mental aspect of this study, the evaluation of the
impact of the three treatments only after acute
administration, that must be considered. It is well
known that FEV1 steady state with tiotropium is
reached within 48 h, while continued improvements
in FVC can be expected over or beyond the first
week of therapy.23 The continued increases in FVC
beyond 48 h suggest that maintenance bronchodi-
lator therapy is required to achieve maximal
changes in hyperinflation. This is the likely ex-
planation of the fact that FVC did not change in a
significant manner after the inhalation of tiotro-
pium alone, and the observed lack of improvement
in IC 30min after tiotropium administration that
contrasts with the documentation of Celli et al.24 of
a fast increase in this parameter after long-term
administration of this long-acting anticholinergic
agent.
Since the evaluation of the impact of the three
treatments only after acute administration can be
considered a potential bias, the real value of
adding salmeterol twice daily to tiotropium once
daily or, alternatively, tiotropium once daily to
salmeterol twice daily in the management of COPD
will be determined only after long-term adminis-
tration of this combination.
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